InvestorsHub Logo

Zardiw

06/03/19 8:38 AM

#50369 RE: mick #50361

DDAmanda® Chart on: $ACRL ACRL #ACRL :





z

nfrequent

01/28/20 12:14 PM

#50814 RE: mick #50361

SVTE UPLISTED. Now OTC PINK Current. What do you think Mick?

$Pistol Pete$

02/04/20 2:01 AM

#50899 RE: mick #50361

$BPMX “Following the closing of the merger, the combined company will also evaluate BioPharmX's Phase 3 ready proprietary topical minocycline gel programs for a strategic partnership, co-development or other non-dilutive value creation strategy. This product has previously been studied by BioPharmX in the treatment of inflammatory lesions of acne vulgaris and papulopustular rosacea"

https://www.prnewswire.com/news-releases/biopharmx-and-timber-pharmaceuticals-announce-entry-into-merger-agreement-300994838.html

Baxy

06/15/20 11:24 AM

#51464 RE: mick #50361

$MMMM O/S 10m, $5m revs per quarter, Market cap $3m. Pink current. Huge growth

$Pistol Pete$

08/24/20 1:42 PM

#51824 RE: mick #50361

$ACI Albertsons initiated with a Buy at Citi Citi analyst Paul Lejuez initiated coverage of Albertsons with a Buy rating and $22 price target. The company is "winning in this uncertain environment" and is well positioned to capitalize on eat at home trends, Lejuez tells investors in a research note. Following its initial public offering on June 26, the stock is down 3%, presenting an attractive entry point for a pure play food retailer, says the analyst.

Read more at:
https://thefly.com/landingPageNews.php?id=3128554

$Pistol Pete$

08/24/20 1:44 PM

#51825 RE: mick #50361

$ECOR ECOR Analyst Research

ECOR Analyst Ratings
CONSENSUS
Strong Buy
Based on 2 analysts offering recommendations for ecor in the last 3 months.

Analyst Firms Making Recommendations
H C WAINWRIGHT
NOBLE FINANCIAL
Analyst
$3.5
Based on analysts offering 12 month price targets for ECOR in the last 3 months. The average price target is $3.5 with a high estimate of $4 and a low estimate of $3. Sign in to your SmartPortfolio to see more analyst recommendations.

https://www.nasdaq.com/market-activity/stocks/ecor/analyst-research